Skip to Content
Søg Menu

First-line treatment with Relatlima + nivolumab demonstrated significant PFS benefit in patients with advanced melanoma

Immune checkpoint inhibitor therapy has revolutionized the treatment of patients with advanced melanoma. In this MEDtalk Evan J Lipson presents a human IgG4 LAG-3-blocking antibody in combination with nivolumab form the RELATIVITY-047 study.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Ten-Year Survival Data from a Groundbreaking Trial for the Treatment of Metastatic Melanoma

/ BestPractice Nordic
ESMO24Melanom

The Ultimate Proof That Immunotherapy Can Be Curative for Metastatic Malignant Melanoma

/ BestPractice Nordic
ESMO24Melanom
Rasmus Friis

Fejring af langtidsdata for behandling af metastatisk malign melanom – og døren til neoadjuverende behandling er ved at åbne sig

/ Rasmus Blechingberg Friis
ESMO24Melanom Play the Video 09:51
Marco Donia

Significant Updates on Neoadjuvant Treatments for Stage 3 Melanoma

/ Marco Donia
ESMO24MelanomImmunterapi Play the Video 4:39
Hildur Helgadottir

The Effect of Adjuvant Treatment on Overall Survival in Melanoma Stage III Patients

/ Hildur Helgadottir
ESMO24Melanom Play the Video 6:50
Hanna Grauers Wiktorin

Objective Responses and Stable Disease in Patients with Immunotherapy Refractory Advanced Malignant Melanoma

/ Hanna Grauers Wiktorin
ESMO24Melanom Play the Video 07:24
Marco Donia

ESMO 2023 Highlights: Developments in Melanoma

/ Marco Donia
ESMO23Melanom Play the Video 03:46

Significant PFS Benefit for the Nivolumab + Relatlimab Combination for Patients with Unresectable or Metastatic Melanoma

/ BestPractice Nordic
ASCO23Melanom

Adjuvant Pembrolizumab Continue to Demonstrate Significant Improvements for Patients with Stage IIB/IIC Melanoma

/ BestPractice Nordic
ASCO23Melanom
Back to top